|
|
|
| Clinical effect of Ruxolitinib in the treatment of JAK2V617F-positive myeloproliferative neoplasms |
| ZOU Min |
| Department of Hematology, Ganzhou People′s Hospital, Jiangxi Province, Ganzhou 341000, China |
|
|
|
|
Abstract Objective To explore the clinical effect of Ruxolitinib in the treatment of JAK2V617F-positive myeloproliterative neoplasms (MPN). Methods A total of 60 JAK2V617F positive MPN patients admitted to Ganzhou People′s Hospital from July 2017 to July 2019 were selected as the study subjects, and they were divided into observation group and control group by random number table method, with 30 patients in each group. The control group was treated with oral Hydroxycarbamide Tablets, while observation group was treated with oral Ruxolitinib. Total MPN-10 score,myelofibrosis (MF) grading assessment, spleen diameter, relative expression levels of JAK2V617F gene in bone marrow were compared between two groups before and after treatment, and the occurrence of adverse reactions between two groups during treatment was recorded. Results After treatment, the MPN-10 and MF scores of the observation group were lower than those of the control group, and the spleen diameter of the observation group was shorter than that of the control group,the differences were statistically significant (P＜0.05).The relative expression level of JAK2V617F gene in the observation group were lower than those in the control group after 6 months and 1 year of treatment, the differences were statistically significant (P＜0.05). There was no significant difference in the total incidence of adverse reactions between the two groups (P＞0.05). Conclusion Ruxolitinib can significantly reduce expression level of JAK2V617F gene in patients with JAK2V617F-positive MPN, reverse myelofibrosis level, and improve clinical curative effect.
|
|
|
|
|
|
| [1] |
肖志坚.我国骨髓增殖性肿瘤的诊治现状及挑战[J].诊断学理论与实践，2020，19（2）：101-103.
|
| [2] |
张怡安，刘澎.骨髓增殖性肿瘤与淋巴系统肿瘤[J].中国实用内科杂志，2019，39（2）：47-50.
|
| [3] |
胡晓，於秋燕，徐文，等.骨髓增殖性肿瘤患者JAK2V617F突变与临床特征的关联性分析及其临床意义[J].吉林大学学报（医学版），2019，45（5）：1106-1112.
|
| [4] |
罗萍，吴三云，喻亚兰，等.炎症在骨髓增殖性肿瘤发生与治疗机制中的研究进展[J].临床血液学杂志，2019，32（7）：559-561
|
| [5] |
葸瑞，白海.芦可替尼在骨髓增殖性肿瘤治疗中的应用及对免疫细胞的作用研究进展[J].重庆医学，2019，48（21）：3739-3742.
|
| [6] |
方三高，魏建国.WHO（2018）皮肤肿瘤分类——淋巴造血组织肿瘤[J].临床与实验病理学杂志，2019（4）：502.
|
| [7] |
章志福，汤礼宾，孙洪波，等.Ph 染色体/BCR-ABL 融合基因阴性骨髓增殖性肿瘤患者不同疗效评价时期的症状负荷评估[J].国际肿瘤学杂志，2019，46（10）：595-600.
|
| [8] |
张震东，曾庆曙，倪静.慢性粒细胞白血病合并骨髓纤维化患者疗效的观察[J].临床血液学杂志，2019，32（1）：20-23.
|
| [9] |
张强，张艺佳，徐湘民,等.骨髓增生疾病JAK2 V617F 突变快速检测体系的建立[J].中华医学遗传学杂志，2019，36（10）：980-984.
|
| [10] |
史妍，杨建征，石光，等.骨髓增殖性肿瘤发病机制及预后转归的研究进展[J].中国实验诊断学，2020，24（3）：525-530.
|
| [11] |
杜晓雷，陈雯雯，张飞虎.骨髓细胞形态观察联合骨髓活检在JAK2V617F 突变阳性骨髓增殖性肿瘤中的应用价值[J].安徽医学，2019，40（7）：787-789.
|
| [12] |
王雨婷，范续，陈均法，等.芦可替尼联合化疗治疗急性巨核细胞白血病合并骨髓纤维化1 例[J].浙江医学，2020，42（7）：743，755.
|
| [13] |
秦福丽，郭志强.JAK2 阳性骨髓增殖性肿瘤患者65 例临床特征分析[J].临床内科杂志，2020，37（10）：737-739.
|
| [14] |
张叶华，郭素丽.JAK2 V617F、DNMT3A、NPM1 和FLT3-ITD 基因突变与骨髓增殖性肿瘤预后的相关性分析[J].中国医学装备，2019，16（2）：37-42.
|
| [15] |
吴晶，王艳.芦可替尼联合药物和allo-HSCT 治疗骨髓纤维化的研究进展[J].检验医学与临床，2019，16（20）：3067-3070.
|
|
|
|
